Related Experiment Video

Updated: Jun 29, 2025

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.3K

Recent Discovery and Development of Inhibitors that Target CDK9 and Their Therapeutic Indications

Yuming Zhang1,2, Lianhai Shan3, Wentao Tang1

  • 1Department of Neurology, Neuro-system and Multimorbidity Laboratory and State Key Laboratory of Biotherapy and Cancer Center and National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, 610041 Sichuan, China.

Journal of Medicinal Chemistry
|April 2, 2024
PubMed

Insights

Cyclin-dependent kinase 9 (CDK9) inhibitors show promise for treating leukemia and lymphoma. Novel strategies are needed to overcome challenges like low efficacy and adverse reactions for successful clinical application.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • Cyclin-dependent kinase 9 (CDK9) is crucial for gene transcription, cell cycle regulation, DNA repair, and differentiation.
  • CDK9 inhibition is a promising strategy for antitumor therapies, particularly for leukemia and lymphoma.
  • Existing CDK9 inhibitors face clinical challenges, including limited efficacy and adverse effects, necessitating new approaches.

Purpose of the Study:

  • To provide a comprehensive overview of CDK9 inhibitors.
  • To analyze structural characteristics, biological functions, and preclinical data of various CDK9 inhibitors.
  • To explore novel strategies for developing effective CDK9-targeted therapies.

Main Methods:

  • Literature review and analysis of existing data on CDK9 inhibitors.
  • Examination of diverse inhibitor classes: pan-inhibitors, selective inhibitors, dual-target inhibitors, degraders, PPI inhibitors, and natural products.
  • Discussion of chemical structures, structure-activity relationships (SARs), biological activities, selectivity, and therapeutic potential.

Main Results:

  • Overview of structural features and biological roles of CDK9 inhibitors.
  • Analysis of preclinical status and therapeutic potential across different inhibitor categories.
  • Identification of challenges and opportunities in CDK9-targeted cancer therapy.

Conclusions:

  • CDK9 inhibitors represent a significant area of research for cancer treatment.
  • Diverse inhibitor types offer various therapeutic avenues, but clinical translation requires further optimization.
  • Exploration of novel inhibitor designs and strategies is essential for overcoming current limitations and achieving clinical success.

More Related Videos

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.2K
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

14.9K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
5.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K